Skip to main content

TransMedics Group, Inc.

corporate_fare Company Profile

TransMedics Group, Inc.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed TMDX - Latest Insights

TMDX
Apr 29, 2026, 9:27 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
TMDX
Apr 10, 2026, 7:48 AM EDT
Filing Type: DEF 14A
Importance Score:
8
TMDX
Feb 27, 2026, 8:25 AM EST
Filing Type: 8-K
Importance Score:
7
TMDX
Feb 27, 2026, 7:03 AM EST
Source: Dow Jones Newswires
Importance Score:
7
TMDX
Feb 24, 2026, 4:16 PM EST
Filing Type: 10-K
Importance Score:
8
TMDX
Feb 24, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
TMDX
Feb 04, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
TMDX
Jan 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8